Jaguar Health To Present Phase 3 OnTarget Trial Results For Its Cancer Supportive Care Drug Crofelemer On Or Before July 23, 2024
Portfolio Pulse from Benzinga Newsdesk
Jaguar Health, Inc. (NASDAQ:JAGX) will present results from its Phase 3 OnTarget trial for the cancer supportive care drug Crofelemer by July 23, 2024. The webcast will include updates on Jaguar's cancer supportive care portfolio and feature insights from the scientific team, patient advocates, and oncology experts.
June 12, 2024 | 12:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jaguar Health will present Phase 3 trial results for Crofelemer by July 23, 2024. The webcast will provide updates on their cancer supportive care portfolio, potentially impacting the stock price.
The announcement of Phase 3 trial results for Crofelemer, a key drug in Jaguar's cancer supportive care portfolio, is likely to generate investor interest and potentially drive the stock price up. The inclusion of expert insights and patient advocate participation in the webcast adds credibility and may further boost investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100